A-Alpha Bio

Congratulations to David Baker, A-Alpha Scientific Advisor and AlphaSeq Co-Inventor, on winning the 2024 Nobel Prize in Chemistry! This is a much deserved recognition of David's incredible contributions to protein structure prediction and design - and the impact of the work coming out of the Institute for Protein Design, University of Washington. Congratulations as well to Google Deepmind's Demis Hassabis and John M. Jumper! https://lnkd.in/ewJJssDY

Now hiring for a Research Associate I on our Technical Operations team! Come join A-Alpha Bio on our quest to improve human health! Check out the job description and application linked here - we're looking forward to seeing your applications! https://lnkd.in/gcQJaUmd

Now hiring for a Research Associate II on our Technical Operations team! Come join A-Alpha Bio on our quest to improve human health! Check out the job description and application linked here - we're looking forward to seeing your applications! https://lnkd.in/g6myFfXB

Now hiring for a Director of Communications! Come join A-Alpha Bio on our quest to improve human health! This person will lead all corporate communications functions - fostering external understanding of our platforms, therapeutic programs,?corporate strategy, and?industry partnerships. If you know of someone that may be a great fit, please reach out! https://lnkd.in/gAQRmDg6

Now hiring for a Scientist I on our Platform R&D team! Come join A-Alpha Bio on our quest to improve human health! This person will design, execute, and analyze experiments that leverage our AlphaSeq and?AlphaBind?platforms for drug discovery, with a focus on biologic therapeutics. If you know of someone that may be a great fit, please reach out! https://lnkd.in/g4duQ2iU

We are excited to share that A-Alpha Bio has been awarded an additional $14.5M from the United States Department of Defense to enable machine learning models that rapidly predict treatments against possible biological threats. Funding from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense-JPEO-CBRND will expand our partnership with Lawrence Livermore National Laboratory (LLNL) in support of the Generative Unconstrained Intelligent Drug Engineering (GUIDE) program. This announcement follows two years of successful collaboration between A-Alpha and LLNL – beginning with coronaviruses and expanding to multiple undisclosed pathogen families of concern – in which A-Alpha’s AlphaSeq data has been used to train ML models that predict antibody-antigen binding. We look forward to continuing and expanding the partnership! Read more in today's press release: https://lnkd.in/eVKne9eE And thanks to Genetic Engineering & Biotechnology News's Jonathan D. Grinstein, PhD for a great piece: https://lnkd.in/eXB-mufW

Now hiring for a Process Engineer I! Come join A-Alpha Bio on our quest to improve human health! This person will serve as a bridge between our Technical Operations and R&D organizations to improve efficiency and quality, troubleshoot existing processes, and facilitate the transition of new processes. If you know of someone that may be a great fit, please reach out! https://lnkd.in/g38XNqQX

Now hiring for a Scientist I, Antibody Discovery! Come join A-Alpha Bio on our quest to improve human health! This person will join our Biologics Discovery team to execute and optimize antibody discovery and assay development initiatives. If you know of someone that may be a great fit, please reach out! https://lnkd.in/g49BJ2r7

I'm looking forward to attending and presenting at Life Science Innovation Northwest this Thursday! This is one of my favorite annual meetings - a great opportunity to catch up with the local PNW biotech community, which has become more and more vibrant over the eight years I've been attending. I'll be giving an update on what we've been up to at A-Alpha Bio and I'm excited to hear about the new innovations, recent deals, and emerging companies in our region. I hope to see you there!

The A-Alpha team is excited to participate in the Festival of Biologics Annual Meeting in San Diego next week! During the meeting, we will share our latest work on applying AlphaSeq and AlphaBind for immunocytokine engineering.?? ? In his talk, A-Alpha Co-Founder and CEO David Younger will delve into the applications of our platforms to engineer immunocytokine therapeutics using high-throughput experiments and machine learning.? A-Alpha Principal Scientist Emily Engelhart will further present a poster on how our platforms enable the discovery and optimization of highly specific cis-targeting immunocytokines. If you’re attending, catch David’s talk and visit Emily’s poster to learn more.? ? #biotech #immunocytokines #FestivalofBiologics??